Medindia

X

Reportlinker Adds the Future of In Vitro and In Vivo Diagnostic Integration

Wednesday, June 1, 2011 General News J E 4
Advertisement


NEW YORK, May 31, 2011 Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of In Vitro and In Vivo Diagnostic Integration

http://www.reportlinker.com/p0511991/The-Future-of-In-Vitro-and-In-Vivo-Diagnostic-Integration.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

The term in-vitro/in-vivo diagnostics (IV2D) describes the integration of molecular diagnostics with radiology and pathology (imaging), as well as new software and IT platforms. The aims of this integration are to improve patient care. This report provides an overview of current developments in integrated medical diagnostics, covering the emergence of new IV2D methods that combine IVD with current and developing imaging platforms. The drivers of this integration are reviewed including new disease biomarkers, single, combined and emerging imaging systems, as well as IT and patient-centred systems.

Scope of this research

-- Assess the key technologies that will enable in vivo, in vitro diagnostic integration.

-- Understand how IVD methods, biomarkers and imaging methods have been applied to challenges of diagnosis in breast cancer and Alzheimer's disease.

-- Discover how centres of expertise, such as academic departments, are driving new discoveries and offering valuable alliances to diagnostic companies.

-- Understand the factors that are driving healthcare providers to develop improved healthcare programmes through integration in medical diagnostics.

Research and analysis highlights

Today, diagnosis and treatment are increasingly integrated. This reflects developments in several key areas: scientific, diagnosis, evidence-based therapies, advancing personalized care and improved process efficiency. The need to improve patient diagnosis is today driving healthcare providers to improve management and process efficiency.

The rapidly evolving IV2D field offers important opportunities to diagnostic imaging companies. While imaging continues to see important refinements, the development of new imaging systems is challenging. In contrast, substantial numbers of in-vivo biomarkers are being discovered, offering combined "hybrid" integrations with imaging.

Siemens is a global provider of medical diagnostic systems, incorporating primary tests and instrumentation, IT platforms and software solutions, for clinical data handling and processing. Siemens is also developing technologies in the field of integrated diagnostics.

Key reasons to purchase this research

-- What are the major imaging systems in diagnosis and how are they being applied to diagnosis in breast cancer and Alzheimer's disease?

-- What are the business models of some of the major diagnostic companies as they establish new integrated diagnostic and healthcare capabilities?

-- What levels of support and capability do healthcare providers seek from companies offering products and services in the fields of diagnostics?

-- What strategies are the major diagnostic companies taking to reduce costs of the healthcare products and services?

-- Why is it anticipated that the next decade will see substantial growth in the integrated diagnostics field?

Table of Contents

About the author 2

Disclaimer 2

Executive summary 9

The diagnostic-centric healthcare delivery model 9

IV2D Enabling Technologies 10

IV2D Initiatives at Academic Medical Centers 11

Siemens - Medical Diagnostics and Service Model 12

GE Healthcare's Early Health Model 13

Other Imaging Companies Entering the IVD Market 14

Development Perspectives and Market Outlook 15

Chapter 1 The Diagnostic-Centric Healthcare Delivery Model 16

Summary 16

Introduction 17

Integrated diagnostics 18

Biomarkers 21

Breast cancer 21

Challenges in developing biomarkers 27

Chapter 2 IV2D Enabling Technologies 28

Summary 28

Introduction 29

Neurodegenerative disease 29

Alzheimer's disease 29

Computed tomography 30

Magnetic resonance imaging 31

Positron emission tomography 33

Parkinson's disease 34

Functional imaging agents for Parkinson's disease 35

Functional magnetic resonance imaging in Parkinson's disease 36

Cancer 37

Mapping HER-2 positive cells 37

11C-choline PET/CT 37

Dual labels 38

Insulin-like growth factor 38

Cardiovascular disease 39

Traponin/CT Angiography 39

Conclusions 40

Chapter 3 IV2D Initiatives at Academic Medical Centers 41

Summary 41

Introduction 42

The Comprehensive Cancer Imaging Centre, London 43

Centre for Molecular Imaging, Australia 46

The Mayo Clinic, US 48

Conclusions 49

Chapter 4 Siemens - Medical diagnostics and service model 51

Summary 51

Introduction 52

Disease areas 52

Cardiovascular 53

Cardiovascular clinical chemistry 54

Cardiovascular immunoassays 55

Haemostasis 56

Integrated diagnostics and point of care 57

Oncology 58

Siemens' technologies 61

Diagnostics IT 61

Laboratory information 62

Productivity systems 63

Decision support systems 64

Remote monitoring systems 64

eCommerce 64

Siemens information technology 65

Soarian Clinicals 65

Soarian Financials 65

Siemens molecular diagnostic assays 66

Integrated diagnostics 67

The customer's perspective 70

2009 Molecular Summit, Philadelphia, USA 2009 71

Susquehanna Health 73

Conclusions 73

Chapter 5 GE Healthcare's early health model 75

Summary 75

Introduction 76

Early healthcare 76

"Healthymagination" 78

Digital imaging 79

Omnyx Integrated Digital Pathology solution (IDP) 80

GE and Eli Lilly 81

GE and VirtualScopics 82

GE and Merck 82

GE acquires Orbitech 83

The PredictAD Project 83

GE and Clarient 84

GE and ONI Medical Systems 84

Conclusions 84

Chapter 6 Other imaging companies entering the IVD market 86

Summary 86

Introduction 87

Philips Healthcare and Biomerieux 87

HistoRx 89

Bayer Schering Pharma 89

Imaging Diagnostic Systems 91

Given Imaging 92

AION Diagnostics 93

Chapter 7 Development Perspectives and Market Outlook 94

Summary 94

Introduction 95

Integrated diagnostics 96

Emerging developments 98

Breast cancer biomarkers 98

Breast cancer predisposition 100

Detection of breast cancer 101

Diagnosis of breast cancer 102

Metastatic breast cancer 104

Response to therapy 105

Prognosis 106

Alzheimer's disease 107

Prediction of AD 108

Detection of AD 110

Imaged-based biomarkers in AD 112

Market forecasts 116

Biomarkers and risks 118

Driving changes 119

Bibliography 121

Table of figures

Figure 1: The drivers shaping integration in medical diagnostics 18

Figure 2: Biomarkers with utility in the detection, diagnosis and treatment of breast cancer 22

Figure 3: Sources of biomarkers reported with utility in the detection, diagnosis and treatment of breast cancer 23

Figure 4: Types of biomarkers with utility in the detection or diagnosis of breast cancer 24

Figure 5: Single and multiple biomarkers in breast cancer 25

Figure 6: Use of [18F]fluorothymidine (18F-FLT)PET in breast cancer 45

Figure 7: Siemens medical diagnostic IT systems 62

Figure 8: Siemens diagnostic systems organizational structure 67

Figure 9: Siemens diagnostic IT organizational structure 68

Figure 10: Siemens diagnostic detection systems 69

Figure 11: GE's Vscan Visualization Tool 79

Figure 12: Omnyx Integrated Digital Pathology solution (IDP) 81

Figure 13: The Magnotech principle 88

Figure 14: Required capabilities of integrated diagnostic technologies 97

Figure 15: Sources of biomarkers with utility in the detection or diagnosis of breast cancer 99

Figure 16: Types of biomarkers with utility in the detection or diagnosis of breast cancer 100

Table of tables

Table 1: Breast cancer biomarkers indicated for use in the clinic by the American Society of Clinical Oncology (ASCO) 26

Table 2: Siemens dedicated clinical chemistry systems for cardiovascular disease 54

Table 3: Siemens immunoassays for cardiovascular disease 55

Table 4: Siemens haemostasis assays for cardiovascular disease 56

Table 5: Siemens integrated diagnostic systems for cardiovascular disease 57

Table 6: Siemens point-of-care diagnostics for cardiovascular disease 58

Table 7: Siemens diagnostic detection systems 70

Table 8: GE core healthcare capabilities 77

Table 9: Worldwide In vitro diagnostic sales by country 2009-2015, ($bn) 116

Table 10: Worldwide In vitro diagnostic sales by application 2009-2015, ($bn) 117

To order this report:

Diagnostics Industry: The Future of In Vitro and In Vivo Diagnostic Integration

Diagnostics Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
National Minority Quality Forum Launches the U.S. ...
S
STROKE IS URGENT: The Heart and Stroke Foundation ...